Novartis's Brewing Storm: A Cautionary Tale for the Pharmaceutical Industry The latest setback for Swiss drugmaker Novartis has sent shockwaves through the pharmaceutical industry.
Del desiran, an experimental treatment for a muscle wasting disorder, failed a late stage study, dealing a significant blow to the company's pipeline.
Novartis's acquisition strategy, led by CEO Vas Narasimhan, has been a major focus of attention in recent years.